Kinase drug discovery 20 years after imatinib: progress and future directions
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments
Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Background Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma
kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance …
kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance …
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Background ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …
Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA
Purpose: The expanding number of targeted therapeutics for non–small cell lung cancer
(NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform …
(NSCLC) necessitates real-time tumor genotyping, yet tissue biopsies are difficult to perform …
[HTML][HTML] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of …
WD Travis, E Brambilla, M Noguchi… - Journal of thoracic …, 2011 - Elsevier
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, MB Beasley, DA Chitale… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
Targeting the EGFR signaling pathway in cancer therapy
P Seshacharyulu, MP Ponnusamy… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …
recently been made, wherein EGFR and its family members have emerged as useful …
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
The epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB
family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival …
family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival …